RhumbLine Advisers’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

RhumbLine Advisers’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$221K	Buy	7,381 +409	+6%	+$13.5K	﹤0.01%	3071
2025 Q4	$228K	Buy	6,972 +3,372	+94%	+$109K	﹤0.01%	3116
2025 Q3	$125K	Sell	3,600 -255	-7%	-$8.16K	﹤0.01%	3434
2025 Q2	$108K	Sell	3,855 -33	-0.8%	-$885	﹤0.01%	3502
2025 Q1	$97.7K	Sell	3,888 -935	-19%	-$23.6K	﹤0.01%	3404
2024 Q4	$133K	Hold	4,823	–	–	﹤0.01%	3386
2024 Q3	$139K	Buy	4,823 +245	+5%	+$6.67K	﹤0.01%	3395
2024 Q2	$113K	Buy	4,578 +814	+22%	+$23.1K	﹤0.01%	3481
2024 Q1	$121K	Buy	3,764 +728	+24%	+$27.1K	﹤0.01%	3382
2023 Q4	$123K	Hold	3,036	–	–	﹤0.01%	3378
2023 Q3	$105K	Buy	3,036 +55	+2%	+$2.14K	﹤0.01%	3443
2023 Q2	$121K	Buy	+2,981	New	+$122K	﹤0.01%	3444

Other funds holding LKFT

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RhumbLine Advisers's LKFT Position: Q1 2026 in Review

RhumbLine Advisers increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 5.9% in Q1 2026, buying an estimated $13.5K and bringing the position to 7,381 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

RhumbLine Advisers first reported a position in LKFT in Q2 2023 and has held it in 12 quarters since. The position peaked at $228K in Q4 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

RhumbLine Advisers held 7,381 shares of Lakefront Biotherapeutics American Depositary Shares worth $221K as of Q1 2026.
RhumbLine Advisers bought 409 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $13.5K.
Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3071 holding.
RhumbLine Advisers first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2023 and has held it in 12 quarters since.
RhumbLine Advisers's Lakefront Biotherapeutics American Depositary Shares position peaked at $228K in Q4 2025.
90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.